Working within the Molecular Pathology Research Laboratory, led by Professor Hamish Scott, I am involved in a national collaborative effort to bring precision medicine to patients recruited into molecular screening trials by facilitating cutting edge comprehensive genomic profiling of tumours and identifying clinically actionable mutations in these tumours. Building on my extensive research and diagnostic experience, and expanding on the large range of skills I had acquired over 20 years in molecular biology, biochemistry and genetics, my keen interest in developing my career motivated me to complete a Master of Diagnostic Genomics degree (awarded in 2021) through the Queensland University of Technology. My interest and motivation was... Read more
Making breakthrough discoveries in the fundamental causes of cancer, and translating these into prevention and treatment.
Working within the Molecular Pathology Research Laboratory, led by Professor Hamish Scott, I am involved in a national collaborative effort to bring precision medicine to patients recruited into molecular screening trials by facilitating cutting edge comprehensive genomic profiling of tumours and identifying clinically actionable mutations in these tumours. Building on my extensive research and diagnostic experience, and expanding on the large range of skills I had acquired over 20 years in molecular biology, biochemistry and genetics, my keen interest in developing my career motivated me to complete a Master of Diagnostic Genomics degree (awarded in 2021) through the Queensland University of Technology. My interest and motivation was further demonstrated when I joined the Human Genetics Society of Australasia (HGSA) SA Branch committee in 2019, and I enjoy actively playing a part in the Australasian genetics community through this committee. I am a passionate genomic scientist, work with an outstanding team of technicians, scientists and clinicians, and continue to contribute to collaborative efforts between research and diagnostics in a pursuit to better understand disease processes and ultimately improve patient outcomes
Bachelor of Science (Honours) University of Adelaide
Excludes commercial-in-confidence projects.
THRF travel Grant 2019, The Hospital Research Foundation, 24/06/2019 - 31/08/2019
Research outputs for the last seven years are shown below. To see earlier years visit ORCID or Scopus
Open access indicates that an output is open access.
Brown, AL, Arts, P, Babic, M, Dobbins, J, Feng, J, Ha, T, Homan, CC, King-Smith, SL, Li, X-C, Brautigan, P, Butcher, C, D'Andrea, RJ, Hahn, CN & Scott, HS and 46 other authors 2020, 'RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML', Blood Advances, vol. 4, no. 6, pp. pp. 1131-1144.
Open access 56 54 3
Neubauer, HA, Tea, MN, Zebol, JR, Gliddon, BL, Stefanidis, C, Moretti, PA, Pitman, MR, Costabile, M, Kular, J, Stringer, BW, Day, BW, Samuel, MS, Bonder, CS, Powell, JA & Pitson, SM 2019, 'Cytoplasmic dynein regulates the subcellular localization of sphingosine kinase 2 to elicit tumor-suppressive functions in glioblastoma', Oncogene, vol. 38, pp. 1151-1165.
Open access 14 14 5
Powell, JA, Pitman, MR, Zebol, JR, Moretti, PA, Neubauer, HA, Davies, LT, Lewis, AC, Dagley, LF, Webb, A I, Costabile, M & Pitson, SM 2019, 'Kelch-like protein 5-mediated ubiquitination of lysine 183 promotes proteasomal degradation of sphingosine kinase 1', Biochemical Journal, vol. 476, no. 21, pp. 3211-3226.
Open access 9 9
Wallington-Beddoe, CT, Bennett, MK, Vandyke, K, Davies, L, Zebol, JR, Moretti, PA, Pitman, MR, Hewett, DR, Zannettino, AC & Pitson, SM 2017, 'Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress', Oncotarget, vol. 8, no. 27, pp. 43602-43616.
Open access 33 32 7
Neubauer, HA, Pham, DH, Zebol, JR, Moretti, PA, Peterson, AL, Leclercq, TM, Chan, H, Powell, JA, Pitman, MR, Samuel, MS, Bonder, CS, Creek, DJ, Gliddon, BL & Pitson, SM 2016, 'An oncogenic role for sphingosine kinase 2', Oncotarget, vol. 7, no. 40, pp. 64886-64899.
Open access 43 42
Parham, KA, Zebol, JR, Tooley, KL, Sun, WY, Moldenhauer, LM, Cockshell, MP, Gliddon, BL, Moretti, PA, Tigyi, G, Pitson, SM & Bonder, CS 2015, 'Sphingosine 1-phosphate is a ligand for peroxisome proliferator-activated receptor-γ that regulates neoangiogenesis', The FASEB Journal, vol. 29, no. 9, pp. 3638-3653.
Open access 62 61 1
Pitman, MR, Powell, JA, Coolen, C, Moretti, PA, Zebol, JR, Pham, DH, Finnie, JW, Don, AS, Ebert, LM, Bonder, CS, Gliddon, BL & Pitson, SM 2015, 'A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties', Oncotarget, vol. 6, no. 9, pp. 7065-7083.
Open access 53 51
Carr, J, Kua, T, Clarke, J, Calvert, J, Zebol, J, Beard, M & Pitson, S 2013, 'Reduced sphingosine kinase 1 activity in dengue virus type-2 infected cells can be mediated by the 3' untranslated region of dengue virus type-2 RNA', Journal of General Virology, vol. 94, part 11, pp. 2437-2448.
Open access 24 24 3
Jarman, KE, Moretti, PA, Zebol, JR & Pitson, SM 2010, 'Translocation of sphingosine kinase 1 to the plasma membrane is mediated by calcium- and integrin-binding protein 1', Journal of Biological Chemistry, vol. 285 no. 1, pp. 483-492.
Zebol, JR, Hewitt, NM, Moretti, PA, Lynn, HE, Lake, JA, Li, P, Vadas, MA, Wattenberg, BW & Pitson, SM 2009, 'The CCT/TRiC chaperonin is required for maturation of sphingosine kinase 1', The International Journal of Biochemistry and Cell Biology, vol. 41 no. 4, pp. 822-827.
Open access 18 16
External engagement & recognition
|Institute of Medical and Veterinary Science||AUSTRALIA|
|QIMR Berghofer Medical Research Institute||AUSTRALIA|
|University of Adelaide||AUSTRALIA|
|University of New South Wales||AUSTRALIA|
|University of South Australia||AUSTRALIA|
|University of Tennessee||UNITED STATES|
|Walter and Eliza Hall Institute of Medical Research||AUSTRALIA|